KEGG   NETWORK: N00253Help
Entry
N00253                      Network                                

Name
Amplified ERBB2 to PI3K signaling pathway
Definition
EGF -> (ERBB2*+EGFR) -> PI3K -> PIP3 -> AKT -> MTOR -> S6K
  Expanded
1950 -> (2064v3+1956) -> (5290,5291,5293) -> C05981 -> (207,208,10000) -> 2475 -> (6198,6199)
Class
nt06214 PI3K signaling
nt06261 Gastric cancer
Type
Variant
Pathway
hsa05226  Gastric cancer
Disease
H00018  Gastric cancer
Gene
1950  EGF; epidermal growth factor
2064  ERBB2; erb-b2 receptor tyrosine kinase 2
1956  EGFR; epidermal growth factor receptor
5290  PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha
5291  PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta
5293  PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta
207  AKT1; AKT serine/threonine kinase 1
208  AKT2; AKT serine/threonine kinase 2
10000  AKT3; AKT serine/threonine kinase 3
2475  MTOR; mechanistic target of rapamycin kinase
6198  RPS6KB1; ribosomal protein S6 kinase B1
6199  RPS6KB2; ribosomal protein S6 kinase B2
Variant
2064v3  ERBB2 amplification
Reference
  Authors
Ciardiello F, Tortora G
  Title
EGFR antagonists in cancer treatment.
  Journal
N Engl J Med 358:1160-74 (2008)
DOI:10.1056/NEJMra0707704
Reference
  Authors
Riquelme I, Saavedra K, Espinoza JA, Weber H, Garcia P, Nervi B, Garrido M, Corvalan AH, Roa JC, Bizama C
  Title
Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy.
  Journal
Oncotarget 6:24750-79 (2015)
DOI:10.18632/oncotarget.4990
Reference
  Authors
Wadhwa R, Song S, Lee JS, Yao Y, Wei Q, Ajani JA
  Title
Gastric cancer-molecular and clinical dimensions.
  Journal
Nat Rev Clin Oncol 10:643-55 (2013)
DOI:10.1038/nrclinonc.2013.170
Reference
  Authors
Bertotti A, Sassi F
  Title
Molecular Pathways: Sensitivity and Resistance to Anti-EGFR Antibodies.
  Journal
Clin Cancer Res 21:3377-83 (2015)
DOI:10.1158/1078-0432.CCR-14-0848

DBGET integrated database retrieval system